Monopar Therapeutics (NASDAQ:MNPR) Downgraded by Zacks Investment Research to Hold

Monopar Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Monopar Therapeutics Downgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Monopar Therapeutics (NASDAQ:MNPR) Downgraded by Zacks Investment Research to Hold

Monopar Therapeutics (MNPR) Upgraded by Zacks Investment Research to Buy

Monopar Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Monopar Therapeutics Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Monopar Therapeutics (MNPR) Upgraded by Zacks Investment Research to Buy